Literature DB >> 2530962

Interaction of 5'-deoxy-5-fluorouridine and methotrexate. A basis for reduced methotrexate toxicity.

D Bowen1, T J Robbins, R M White.   

Abstract

Methotrexate (MTX) toxicity is reduced significantly by a non-toxic dose of 5'-deoxy-5-fluorouridine (5'dFUr). Changes in the hematopoietic system (platelets, erythrocytes, leukocytes, and hematocrit), ileal tissue, and body weight were used as parameters to assess toxicity. MTX treatment alone resulted in: (a) a reduction of body weight; (b) significantly morphological changes in ileal tissue; and (c) a marked decrease in the hematopoietic parameters. Sequential treatment with MTX followed by 5'dFUr resulted in reversal of MTX depression of animal body weight and ileal tissue necrosis, and partial reversal in MTX toxicity to the hematopoietic system. Also, for all parameters studied, there were no significant differences between scheduling of MTX after a priming dose of 5'dFUr, 5'dFUr alone, and control. Hence, this study suggests that 5'dFUr is a pharmacological antidote for MTX toxicity, and, therefore, 5'dFUr in combination with MTX may provide a basis whereby more intense and effective MTX therapy may be given.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2530962     DOI: 10.1007/bf00303130

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  13 in total

1.  Dose-response is alive and well.

Authors:  V T DeVita
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

2.  The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells.

Authors:  E Cadman; R Heimer; C Benz
Journal:  J Biol Chem       Date:  1981-02-25       Impact factor: 5.157

3.  Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

Review 4.  The pharmacology and clinical use of methotrexate.

Authors:  J Jolivet; K H Cowan; G A Curt; N J Clendeninn; B A Chabner
Journal:  N Engl J Med       Date:  1983-11-03       Impact factor: 91.245

5.  5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling.

Authors:  J H Mulder; T Smink; L M van Putten
Journal:  Eur J Cancer Clin Oncol       Date:  1981-07

6.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.

Authors:  W Hryniuk; M N Levine
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

7.  Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

8.  Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine.

Authors:  K M Connolly; R B Diasio; R D Armstrong; A M Kaplan
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

9.  5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.

Authors:  R D Armstrong; E Cadman
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  Mechanism of cytotoxic activity of 5'-deoxy-5-fluorouridine.

Authors:  R D Armstrong; K M Connolly; A M Kaplan; E Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.